Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Posard Matthew L., holds the title of Director at HALOZYME THERAPEUTICS, INC..
On 2026-11-18, the insider transacted 5,000 shares.The shares were transacted at a weighted average price of $96.43 per share, resulting in a total market-relevant value of $482K.
Posard Matthew L. (Director) sold $482K of $HALO
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.